Switzerland's SOPHiA GENETICS Q2 revenue rises on Liquid Biopsy growth

Sophia Genetics SA

04/08/2026 12:05

Overview
Switzerland AI precision medicine firm's Q2 revenue grew 27% yr/yr
Adjusted EBITDA loss for Q2 improved 27% yr/yr
Company raised 2026 revenue guidance to $94-96 mln, up from prior range

Outlook
SOPHiA GENETICS raises 2026 revenue guidance to $94 mln-$96 mln from $92 mln-$94 mln
Company expects 2026 adjusted EBITDA loss between $29 mln and $32 mln
SOPHiA GENETICS expects to approach adjusted EBITDA breakeven by end of 2026

Result Drivers
U.S. VOLUME GROWTH - Co said Q2 revenue was driven by 60% volume growth in the U.S.
LIQUID BIOPSY EXPANSION - Co reported 80% yr/yr revenue growth in Liquid Biopsy segment in Q2
BIOPHARMA PARTNERSHIPS - Co said accelerating BioPharma growth was supported by new companion diagnostic programs with AstraZeneca

Company press release: ID:nPn1RFkfza

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
 
$23.30 mln
 
Q2 Adjusted Gross Margin
 
72.10%
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)